THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, May 17, 2021
Covistat is presenting preclinical data at the American Thoracic Society annual meeting.
FREMONT, CA: Ensysce Biosciences agrees with a business combination with Leisure Acquisition, a special purpose acquisition company formed to effect a merger, acquisition, or similar business combination, announces that Ensysce’s subsidiary, Covistat, will be presenting at the American Thoracic Society Annual Meeting to be held May 14-19, 2021. ATS 2021 showcases the latest innovations and discoveries in respiratory science, patient care, and global respiratory health.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Covistat will present a summary of its findings that it believes shows the ability of nafamostat, offered to airways, to inhibit SARS-CoV-2 viral infection and increase mucociliary clearance in the human airway, in a poster presentation entitled Nafamostat inhibits SARS-CoV-2 Infection and ENaC activity in Human Airway Epithelial Cells.
This agent has been widely leveraged intravenously in Asia on a safe and effective basis. The company believes it will have great utility in an outpatient setting at low cost and through use as an adjunct to vaccines or where vaccines cannot be readily evaluated. The companies completed their Phase 1 trial with oral nafamostat in November of 2020 and now are progressing to Phase 2 in COVID-19 patients that are not hospitalized yet are without therapeutic choices.
The company believes nafamostat, taken by mouth, could significantly change treatment options because people newly infected with the virus v=can use it outside of hospitals. The current expectation is that the medication could keep the disease from progressing and prevent unnecessary hospitalizations. Nafamostat is also a component of Ensysce’s multi-pill abuse resistance platform that is poised to enter a Phase 1 trial, a significant clinical milestone for protecting opioid overdose. Ensysce has an intellectual property that it believes hard the use of nafamostat for overdose protection of prescription drugs and treating Cystic Fibrosis. Covistat is c presently exploring the use of oral nafamostat for treatment of COVID-19 and is expected to launch a Phase 2 trial during the second half of 2021.
More in News